Clayton Hardman

Clayton Hardman

Auto-generated profile, based on publicly available information

Clayton Hardman

Arcus Biosciences, Inc

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2017 in Science
Verified
Journal Article
Closed access
PDF file
PWPaul A. Wender
Paul A. Wender
CHClayton T. Hardman
Clayton T. Hardman
SHStephen Ho
Stephen Ho
MJMatthew S. Jeffreys
Matthew S. Jeffreys
JMJana K. Maclaren
Jana K. Maclaren
MSMatthew C. Stevens
Matthew C. Stevens
A gram-scale route to bryostatin: Scientists once accumulated 14 tons of the red, bushy, tufted sea creature Bugula neritina to extract 18 grams of bryostatin 1. The macrocyclic organic compound is under study for treatment of HIV, cancer, and Alzheimer's disease but has proven frustratingly scarce. Wender et al. report a 29-step chemical synthesis of bryostatin 1 that proceeds in 4.8% overall yield and provides gram quantities of the compound (see the Perspective by Lanman). Intermediates along the pathway can be straightforwardly modified to produce analogs, two of which were prepared en route and studied in vitro. Science , this issue p. 218 ; see also p. 166

20 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CHClayton Hardman
Clayton Hardman
SHStephen Ho
Stephen Ho
ASAkira Shimizu
Akira Shimizu
QLQuang Luu-Nguyen
Quang Luu-Nguyen
JSJack L. Sloane
Jack L. Sloane
PWPaul A. Wender
Paul A. Wender
Bryostatin 1 is a marine natural product under investigation for HIV/AIDS eradication, the treatment of neurological disorders, and enhanced CAR T/NK cell immunotherapy. Despite its promising activity, bryostatin 1 is neither evolved nor optimized for the treatment of human disease. Here we report the design, synthesis, and biological evaluation of several close-in analogs of bryostatin 1. Using a function-oriented synthesis approach, we synthesize a series of bryostatin analogs designed to maintain affinity for bryostatin’s target protein kinase C (PKC) while enabling exploration of their divergent biological functions. Our late-stage diversification strategy provides efficient access to a library of bryostatin analogs, which per our design retain affinity for PKC but exhibit variable PKC translocation kinetics. We further demonstrate that select analogs potently increase cell surface expression of CD22, a promising CAR T cell target for the treatment of leukemias, highlighting the clinical potential of bryostatin analogs for enhancing targeted immunotherapies.

19 January 2021 in Cell Chemical Biology
Verified
Journal Article
Closed access
EAEfrat Abramson
Efrat Abramson
CHClayton Hardman
Clayton Hardman
ASAkira J. Shimizu
Akira J. Shimizu
SHSoonmyung Hwang
Soonmyung Hwang
LHLynda D. Hester
Lynda D. Hester
MKMichael D. Kornberg
Michael D. Kornberg

5 February 2025 in Organic Process Research & Development
Verified
Journal Article
Closed access
CHClayton Hardman
Clayton Hardman
AMArtur K. Mailyan
Artur K. Mailyan
GMGuillaume Mata
Guillaume Mata
JBJoel W. Beatty
Joel W. Beatty
SDSamuel L. Drew
Samuel L. Drew
KLKenneth V. Lawson
Kenneth V. Lawson

25 September 2017 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
YYYang Yang
Yang Yang
CHClayton Hardman
Clayton Hardman
Chiral 2-substituted-6-methyl 2,3-dihydropyidinones 9, which can be facilely obtained from an asymmetric vinylogous Mannich reaction (VMR) with 1,3-bis-trimethysily enol ether, were used as versatile intermediates in constructing chiral polyfunctional piperidine-based compounds. The 6-methyl group of such compounds can be conveniently functionalized via alkylation and acylation reactions to provide efficient entries to the synthesis of a variety of chiral multi-substituted piperidine-based compounds. Further elaboration of the corresponding intermediates also provided access to polyfunctional indolizidine-based compounds. These methods were showcased in an asymmetric synthesis of 2,6-di-substituted piperidine compound 13, reported as the key intermediate in the synthesis of (+)-calvine and a natural alkaloid (−)-indolizidine 209D. Furthermore, selective C5 iodination of compound 9 enabled the installation of additional functional groups at this position. Finally, we demonstrated that the oxidative cleavage of 2-substituted-6-methyl-2,3-dihydropyidinones is a practical and efficient method for the enantioselective synthesis of β-amino acids, which can undergo further intra-molecular cyclization to give the corresponding chiral four-membered β-lactam derivatives.

5 June 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AMArtur K. Mailyan
Artur K. Mailyan
GMGuillaume Mata
Guillaume Mata
JBJoel W. Beatty
Joel W. Beatty
SDSamuel L. Drew
Samuel L. Drew
JFJeremy Fournier
Jeremy Fournier
KLKenneth V. Lawson
Kenneth V. Lawson